Technology | 2022.10.18
Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
- Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis - Kyverna\'s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]lupus-nephritis-301651246.html
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1575
Instagram is adding automatic in-app text translation - The Verge views: 1508